Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05308446	TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	Phase Phase 2	Date Added 2022-04-04	Location Arizona, United States California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo	Tags MSS/ MMRp
NCT ID NCT06102902	TitleTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC	Phase Phase 1	Date Added 2023-10-26	Location California, United States Colorado, United States Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs BET Bromodomain Inhibitor ZEN-3694, encorafenib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03368963	TitleTAS102 in Combination With NAL-IRI in Advanced GI Cancers	Phase Phase 1, Phase 2	Date Added 2017-12-11	Location Georgia, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02465060	TitleTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Phase Phase 2	Date Added 2015-06-08	Location Alabama, United States Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Guam Puerto Rico	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib	Tags MSS/ MMRp
NCT ID NCT02693535	TitleTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Phase Phase 2	Date Added 2016-02-26	Location Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03599765	TitleSystemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor	Phase Phase 2	Date Added 2018-07-26	Location Arizona, United States Arkansas, United States Hawaii, United States Michigan, United States New Jersey, United States Ohio, United States Texas, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04599140	TitleSX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial	Phase Phase 1, Phase 2	Date Added 2020-10-22	Location Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs CXCR1/2 Inhibitor SX-682, Nivolumab	Tags MSS/ MMRp
NCT ID NCT04653480	TitleSurufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC	Phase Phase 2	Date Added 2020-12-04	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Chemotherapy, Surufatinib, Toripalimab	Tags MSS/ MMRp
NCT ID NCT06014502	TitleStudy to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors	Phase Phase 1	Date Added 2023-08-28	Location Arizona, United States California, United States Louisiana, United States Texas, United States	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs IMGS-001	Tags MSI-H/ MMRd
NCT ID NCT04659382	TitleStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2020-12-09	Location France	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Atezolizumab, Bevacizumab, TheraSphere, XELOX	Tags MSS/ MMRp

Showing 21 to 30 of 299 entries